DDR1 inhibition as a new therapeutic strategy for colorectal cancer

The clinical management of metastatic colorectal cancer (mCRC) is still a major challenge. Recently, we discovered that nilotinib, an approved treatment for chronic myeloid leukaemia, inhibits invasive and metastatic properties of CRC cells by targeting the kinase activity of receptor for collagens...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirvent, Audrey, Lafitte, Marie, Roche, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149912/
https://www.ncbi.nlm.nih.gov/pubmed/30250919
http://dx.doi.org/10.1080/23723556.2018.1465882
Descripción
Sumario:The clinical management of metastatic colorectal cancer (mCRC) is still a major challenge. Recently, we discovered that nilotinib, an approved treatment for chronic myeloid leukaemia, inhibits invasive and metastatic properties of CRC cells by targeting the kinase activity of receptor for collagens DDR1 (Discoïdin Domain Receptor tyrosine kinase 1), suggesting that nilotinib could be an effective strategy to treat mCRC.

Ejemplares similares